Search results
Showing 106 to 120 of 1371 results for patients and public
Zanubrutinib for treating relapsed or refractory marginal zone lymphoma [ID5085]
In development [GID-TA10962] Expected publication date: 17 July 2024
Improving baseline assessment for newly diagnosed hypertensive patients and optimising therapy
investigations for newly diagnosed hypertensive patients are conducted at the point of diagnosis. Also to streamline the...
In development [GID-TA10979] Expected publication date: 26 June 2024
In development [GID-TA10877] Expected publication date: 20 November 2024
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development [GID-TA11228] Expected publication date: 25 September 2024
Fosdenopterin for treating molybdenum cofactor deficiency type A [ID6264]
In development [GID-HST10055] Expected publication date: 11 September 2024
Linzagolix for treating moderate to severe symptoms of uterine fibroids [ID6190]
In development [GID-TA11131] Expected publication date: TBC
In development [GID-TA11047] Expected publication date: 21 August 2024
This quality standard covers support and treatment to stop smoking and stop using smokeless tobacco, and harm-reduction approaches for people who are not ready to stop in one go. It describes high-quality care in priority areas for improvement.
View quality statements for QS207Show all sections
Sections for QS207
- Quality statements
- Quality statement 1: Identifying people who use tobacco
- Quality statement 2: Advice
- Quality statement 3: Tobacco cessation support and treatment
- Quality statement 4: Harm-reduction approach
- Quality statement 5: Treatment to stop smoking in hospital
- Update information
- About this quality standard
In development [GID-TA11408] Expected publication date: TBC
In development [GID-TA11418] Expected publication date: 14 August 2024
This quality standard covers ways to reduce suicide and help people bereaved or affected by suicide. It describes high-quality care in priority areas for improvement.
View quality statements for QS189Show all sections
Sections for QS189
- Quality statements
- Quality statement 1: Multi-agency suicide prevention partnerships
- Quality statement 2: Reducing access to methods of suicide
- Quality statement 3: Media reporting
- Quality statement 4: Involving family, carers or friends
- Quality statement 5: Supporting people bereaved or affected by a suspected suicide
- Update information
- About this quality standard
This quality standard covers diagnosing and managing common types of headache in adults and young people (aged 12 and over). It includes tension-type headache, migraine, cluster headache and medication overuse headache. It describes high-quality care in priority areas for improvement.
View quality statements for QS42Show all sections
Sections for QS42
- Quality statements
- Quality statement 1: Classification of headache type
- Quality statement 2: Preventing medication overuse headache
- Quality statement 3: Imaging
- Quality statement 4: Combined treatment for migraine
- Quality statement 5 (placeholder): Raising public and professional awareness
- Update information
- About this quality standard
There are a number of ways you can get involved in the development of our guidance.
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
In development [GID-TA11304] Expected publication date: 13 November 2024